表紙
市場調查報告書

導管相關血流感染疾病(CRBSI)- 流行病學預測 2028年

Catheter-Related Bloodstream Infections (CRBSIs) - Epidemiology Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 909902
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
導管相關血流感染疾病(CRBSI)- 流行病學預測 2028年 Catheter-Related Bloodstream Infections (CRBSIs) - Epidemiology Forecast - 2028
出版日期: 2019年09月01日內容資訊: 英文 100 Pages
簡介

主要7個國家(美國、英國、德國、法國、西班牙、義大利、日本)的導管相關血流感染疾病(CRBSI)的罹患數在2017年估算為66萬7,753人,預計至2028年其數將增加。

本報告提供主要7個國家(美國、英國、德國、法國、西班牙、義大利、日本)的導管相關血流感染疾病(CRBSI)的流行病學的相關調查,疾病概要,各國罹患數及診斷數的變化與預測等相關資訊。

目錄

第1章 重要洞察

第2章 導管相關血流感染疾病(CRBSI):流行病學概要

  • 分佈情形(成果值)
  • 分佈情形(預測值)

第3章 導管相關血流感染疾病(CRBSI):疾病背景和概要

  • 簡介
  • 中心線相關血流感染疾病(CLABSI)和導管相關血流感染疾病(CRBSI)的差異
  • 導管相關血流感染疾病(CRBSI)的原因
    • 微生物
    • 血管內設備
  • 導管相關血流感染疾病(CRBSI)的危險因素
  • 導管相關血流感染疾病(CRBSI)的病因
  • 導管相關血流感染疾病(CRBSI)的診斷
  • 導管相關血流感染疾病(CRBSI)的診斷指南

第4章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的導管相關血流感染疾病(CRBSI)的總罹患數
  • 主要7個國家的導管相關血流感染疾病(CRBSI)的診斷數
  • 主要7個國家的導管相關血流感染疾病(CRBSI)的診斷數:各起炎菌
  • 關鍵意見領袖的意見

第5章 美國的流行病學

  • 假設和根據
  • 總罹患數
  • 總診斷數
  • 診斷數:各起炎菌

第6章 歐洲5個國家的流行病學

  • 德國的流行病學
    • 假設和根據
    • 總罹患數
    • 總診斷數
    • 診斷數:各起炎菌
  • 法國的流行病學
  • 義大利的流行病學
  • 西班牙的流行病學
  • 英國的流行病學

第7章 日本的流行病學

  • 假設和根據
  • 總罹患數
  • 總診斷數
  • 診斷數:各起炎菌

第8章 附錄

  • 調查方法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0375

DelveInsight's ‘Catheter-Related Bloodstream Infections (CRBSIs)- Epidemiology Forecast-2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of CRBSI in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028.

Disease Understanding:

CRBSI refers to bloodstream infection attributed to an intravascular catheter by quantitative culture of the catheter tip or by differences in growth between catheter and peripheral venipuncture blood culture specimens. It is also known as catheter-related sepsis.

In the current scenario, there is no US Food and Drug Administration (FDA) approved drugs/lock solution present in the market, specifically for this indication, and therefore, the availability of new therapies will be the major market driver for the therapeutic market of CRBSI. Only one emerging therapy is present, which is in pipeline, i.e. Mino-Lok Therapy by Citius Pharmaceuticals. Due to non-competitiveness and poor pipeline, the launch of Mino-lok in the US or EU will create a huge hype and will have the only candidate in the CRBSI therapeutic landscape. The treatment of CRBSI is mainly preventive and is done by using off-label antibiotics. So, the need for a potential drug candidate is necessary and urgent.

Epidemiology:

The CRBSI epidemiology division provides insights about historical and current patient pool and forecasted trends for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CRBSI in the 7MM, Total Diagnosed Incident Population of CRBSI in the 7MM, and Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM] scenario of CRBSI in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017-2028.

As per DelveInsight's analysis, total Incident Population of Catheter-Related Bloodstream Infection (CRBSI in the 7MM was found to be 667,753 in 2017 and expected to increase during the forecast period of 2017-2028. The estimates show the incidence was higher in the United States and among the European 5 countries, Germany had the highest incident population of CRBSI followed by France and United Kingdom. On the other hand, Spain had the lowest incident population of CRBSI.

Another estimate of Delveinsight's analysis shows that most of the incident cases of CRBSI are confirmed with specific bacterial species. The estimates show that Gram-positive bacteria are implicated in the majority of the cases of CRBSI in comparison with Gram-negative bacteria.

Report Scope:

  • The report covers detailed overview of Catheter-related Bloodstream Infections explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of Catheter-related Bloodstream Infections
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by type specific cases and severity specific cases of Catheter-related Bloodstream Infections in the 7MM

Key Strengths:

  • 10 Year Forecast of Catheter-related Bloodstream Infections epidemiology
  • 7MM Coverage
  • Total Incident Population of CRBSI
  • Total Diagnosed Incident Population of CRBSI
  • Diagnosed Incidence of CRBSI by Causative Pathogens

Report Assessment:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Catheter-Related Blood Stream Infection (CRBSI) Epidemiology Overview at a Glance

  • 2.1. Total Epidemiology Distribution of CRBSI in 2017
  • 2.2. Total Epidemiology Distribution of CRBSI in 2028

3. Catheter-Related Bloodstream Infection (CRBSI): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Difference between CLABSI and CRBSI
  • 3.3. Causes of Catheter-Related Bloodstream Infection (CRBSI)
    • 3.3.1. Micro-organisms
    • 3.3.2. Intravascular Devices
  • 3.4. Risk Factor Associated with Catheter-Related Bloodstream Infection (CRBSI)
  • 3.5. Pathogenesis of Catheter-Related Bloodstream Infection (CRBSI)
  • 3.6. Diagnosis of Catheter-Related Bloodstream Infection (CRBSI)
  • 3.7. Diagnosis Guidelines Catheter-Related Bloodstream Infection (CRBSI)
    • 3.7.1. Infectious Diseases Society of America (IDSA) Guidelines for CRBSI
    • 3.7.2. Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)
    • 3.7.3. British Intestinal Failure Alliance (BIFA):
    • 3.7.4. European Renal Best Practice (ERBP) Recommendations for Diagnosis of CRBSIs

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Incident Population of CRBSI in the 7MM
  • 4.3. Total Diagnosed Incident Population of CRBSI in the 7MM
  • 4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM
  • 4.5. Some KOL Insights

5. United States Epidemiology

  • 5.1. Assumptions and Rationale
  • 5.2. Total Incident Population of CRBSI in the United States
  • 5.3. Total Diagnosed Incident Population of CRBSI in the United States
  • 5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United States

6. EU5 Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Total Incident Population of CRBSI in Germany
    • 6.1.3. Total Diagnosed Incident Population of CRBSI in Germany
    • 6.1.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Assumptions and rationale
    • 6.2.2. Total Incident Population of CRBSI in France
    • 6.2.3. Total Diagnosed Incident Population of CRBSI in France
    • 6.2.4. Diagnosed Incidence of CRBSI by Causative Pathogens in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Total Incident Population of CRBSI in Italy
    • 6.3.3. Total Diagnosed Incident Population of CRBSI in Italy
    • 6.3.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Assumptions and Rationale
    • 6.4.2. Total Incident Population of CRBSI in Spain
    • 6.4.3. Total Diagnosed Incident Population of CRBSI in Spain
    • 6.4.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Assumptions and Rationale
    • 6.5.2. Total Incident Population of CRBSI in the United Kingdom
    • 6.5.3. Total Diagnosed Incident Population of CRBSI in the United Kingdom
    • 6.5.4. Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom

7. Japan Epidemiology

  • 7.1. Assumptions and Rationale
  • 7.2. Total Incident Population of CRBSI in Japan
  • 7.3. Total Diagnosed Incident Population of CRBSI in Japan
  • 7.4. Diagnosed Incidence of CRBSI by Causative Pathogens in Japan

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

  • TABLE 1: TERMINOLOGY: CLABSI OR CRBSI
  • TABLE 2: VARIOUS RISK FACTORS OF CRBSI
  • TABLE 3: TOTAL INCIDENT POPULATION OF CRBSI IN THE 7MM (2017-2028)
  • TABLE 4: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE 7MM (2017-2028)
  • TABLE 5: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE 7MM (2017-2028)
  • TABLE 6: TOTAL INCIDENT POPULATION OF CRBSI IN THE US (2017-2028)
  • TABLE 7: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE US (2017-2028)
  • TABLE 8: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE US (2017-2028)
  • TABLE 9: TOTAL INCIDENT POPULATION OF CRBSI IN GERMANY (2017-2028)
  • TABLE 10: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN GERMANY (2017-2028)
  • TABLE 11: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN GERMANY (2017-2028)
  • TABLE 12: TOTAL INCIDENT POPULATION OF CRBSI IN FRANCE (2017-2028)
  • TABLE 13: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN FRANCE (2017-2028)
  • TABLE 14: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN FRANCE (2017-2028)
  • TABLE 15: TOTAL INCIDENT POPULATION OF CRBSI IN ITALY (2017-2028)
  • TABLE 16: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN ITALY (2017-2028)
  • TABLE 17: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN ITALY (2017-2028)
  • TABLE 18: TOTAL INCIDENT POPULATION OF CRBSI IN SPAIN (2017-2028)
  • TABLE 19: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN SPAIN (2017-2028)
  • TABLE 20: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN SPAIN (2017-2028)
  • TABLE 21: TOTAL INCIDENT POPULATION OF CRBSI IN THE UK (2017-2028)
  • TABLE 22: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE UK (2017-2028)
  • TABLE 23: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN THE UK (2017-2028)
  • TABLE 24: TOTAL INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017-2028)
  • TABLE 25: TOTAL DIAGNOSED INCIDENT POPULATION OF CRBSI IN THE JAPAN (2017-2028)
  • TABLE 26: DIAGNOSED INCIDENCE OF CRBSI BY CAUSATIVE PATHOGENS IN JAPAN (2017-2028)

List of Figures

  • Figure 1: Types of Central Venous and Arterial Catheter and their sites of insertion
  • Figure 2: Important pathogenic determinants of catheter-related infections
  • Figure 3: Potential sources of infection of a percutaneous intravascular device
  • Figure 4: Total Incident Population of CRBSI in the 7MM (2017-2028)
  • Figure 5: Total Diagnosed Incident Population of CRBSI in the 7MM (2017-2028)
  • Figure 6: Diagnosed Incidence of CRBSI by Causative Pathogens in the 7MM (2017-2028)
  • Figure 7: Total Incident Population of CRBSI in the US (2017-2028)
  • Figure 8: Total Diagnosed Incident Population of CRBSI in the US (2017-2028)
  • Figure 9: Diagnosed Incidence of CRBSI by Causative Pathogens in the US (2017-2028)
  • Figure 10: Total Incident Population of CRBSI in Germany (2017-2028)
  • Figure 11: Total Diagnosed Incident Population of CRBSI in Germany (2017-2028)
  • Figure 12: Diagnosed Incidence of CRBSI by Causative Pathogens in Germany (2017-2028)
  • Figure 13: Total Incident Population of CRBSI in France (2017-2028)
  • Figure 14: Total Diagnosed Incident Population of CRBSI in France (2017-2028)
  • Figure 15: Diagnosed Incidence of CRBSI by Causative Pathogens in France (2017-2028)
  • Figure 16: Total Incident Population of CRBSI in Italy (2017-2028)
  • Figure 17: Total Diagnosed Incident Population of CRBSI in Italy (2017-2028)
  • Figure 18: Diagnosed Incidence of CRBSI by Causative Pathogens in Italy (2017-2028)
  • Figure 19: Total Incident Population of CRBSI in Spain (2017-2028)
  • Figure 20: Total Diagnosed Incident Population of CRBSI in Spain (2017-2028)
  • Figure 21: Diagnosed Incidence of CRBSI by Causative Pathogens in Spain (2017-2028)
  • Figure 22: Total Incident Population of CRBSI in the United Kingdom (2017-2028)
  • Figure 23: Total Diagnosed Incident Population of CRBSI in the United Kingdom (2017-2028)
  • Figure 24: Diagnosed Incidence of CRBSI by Causative Pathogens in the United Kingdom (2017-2028)
  • Figure 25: Total Incident Population of CRBSI in Japan (2017-2028)
  • Figure 26: Total Diagnosed Incident Population of CRBSI in Japan (2017-2028)
  • Figure 27: Diagnosed Incidence of CRBSI by Causative Pathogens in Japan (2017-2028)
Back to Top